MYRIAD GENETICS DL-,01 | 17,360 / -1,11% |
Datum/Vreme | 30.06. / 21:43 |
Promena / Promena(%) | -0,195 / -1,11% |
Tražnja | 17,260 / 289 |
Ponuda | 17,350 / 289 |
Cena na otvaranju | 17,555 |
Prethodno zatvaranje | 17,555 |
Najviša cena | 17,610 |
Najniža | 17,360 |
Obim [EUR] | - |
Obim [Jedinice] | |
Dogovorena cena | 9 |
ISIN | US62855J1043 |
Simbol | MYD |
Berza | gettex |
Vrsta | Stock |
Druge berze
Berza | Poslednja cena | Obim | |
---|---|---|---|
NASDAQ | 18,1700 | ![]() |
494.081 |
IEX | 18,16 | ![]() |
37.071 |
Cboe US | 18,12 | ![]() |
13.334 |
Xetra | 17,510 | ![]() |
0 |
Hannover | 17,450 | ![]() |
0 |
Frankfurt | 17,4500 | ![]() |
0 |
Berlin | 17,425 | ![]() |
0 |
München | 17,625 | ![]() |
0 |
Hamburg | 17,450 | ![]() |
0 |
Düsseldorf | 17,520 | ![]() |
0 |
Stuttgart | 17,325 | ![]() |
0 |
Lang & Schwa.. | 17,065 | ![]() |
|
gettex | 17,360 | ![]() |
|
Quotrix | 17,5350 | ![]() |
|
London Domes.. | 19,45 | 31 | |
TradeGate | 16,450 | 600 |
Vesti
- Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
14.03.2022 / 12:05 - GlobeNewswire - Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
12.03.2022 / 01:05 - GlobeNewswire - Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
08.03.2022 / 13:22 - GlobeNewswire - Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
02.03.2022 / 22:30 - GlobeNewswire - Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
24.02.2022 / 15:00 - GlobeNewswire
Kliknite na
da aktivirate push kvote.
